Figure 1.

MTBP is identified as a poor prognostic biomarker of stage I lung adenocarcinoma.

Notes: (A) Flowchart of the derivation and validation of genes associated with prognosis of stage I lung adenocarcinoma. (B) Survival curves of stage I adenocarcinoma patients with low expression vs high expression of MTBP mRNA generated based on data from three training datasets (GSE30219, GSE37745, GSE50081) and a validation dataset (GSE13213). (C) Scatter diagram representing the MTBP mRNA expression in stage I lung adenocarcinoma tissues and normal adjacent tissues. (D) Representative MTBP protein expression levels in early-stage lung adenocarcinoma tissues determined by immunohistochemical staining. (E) Kaplan–Meier survival plots for analysis of the level of MTBP expression in low-expression (−/+) and high-expression groups (++/+++) for evaluating the prognosis of early-stage lung adenocarcinoma patients.

Abbreviations: DEGs, differentially expressed genes; FC, fold change ratio of long-survival group to short-survival group; K-M, Kaplan–Meier; MTBP, MDM₂ binding protein; OS, overall survival.